Doxazosin Tablet
Product Images NDC 51655-130

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 51655-130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (51655 130 52 Rev A 02 23)

Label (51655 130 52 Rev A 02 23)
This is a description of a medication with a National Drug Code (NDC) of 51655-130-52. The medication is Doxazosin and comes in a tablet form with a strength of 4 mg. The package contains 30 tablets and is only available with a prescription. The recommended dosage can be found in the package insert. The medication should be stored at a temperature between 25°C-30°C (77°F-86°F) and kept out of reach of children. The tablets are made by Upsher-Smith Laboratories, LLC and have been repackaged by Northwind Pharmaceuticals with a GTIN of 00351655130520. The lot number for this medication is 0000000000 and the serial number is 000000000000000. The expiration date is 00/00/0000.*
FDA Label Image

Chemical Structure (Doxazosin 01)

Chemical Structure (Doxazosin 01)
FDA Label Image

Table 3 (Doxazosin 02)

Table 3 (Doxazosin 02)
The text presents several studies related to the maximum flow rate and symptom score of patients with BPH who received different dosages of doxazosin or placebo. The studies were conducted with a modified Boyarsky questionnaire and AUA questionnaire. The results showed that the maximum flow rate increased and the symptom score decreased in patients who received doxazosin compared to those who received a placebo. There were statistically significant differences in some of the mean changes.*
FDA Label Image

Figure 1 (Doxazosin 03)

Figure 1 (Doxazosin 03)
The text provides a figure (Study 1) that shows the mean change in total symptom score and the mean increase in maximum urinary flow rate from baseline in 47 people after treatment with Doxazosin for varying durations (week 0 to week 14). The figure suggests a statistically significant improvement in both the symptom score and urinary flow rate compared to placebo, with the maximum improvement observed after eight weeks of treatment.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.